Eplontersen Continues to Show Long-Term Effectiveness in hATTR Polyneuropathy
Eplontersen Continues to Show Long-Term Effectiveness in hATTR Polyneuropathy
About this item
Full title
Author / Creator
Publisher
Cranbury: Intellisphere, LLC
Journal title
Language
English
Formats
Publication information
Publisher
Cranbury: Intellisphere, LLC
Subjects
More information
Scope and Contents
Contents
Newly announced phase 3 findings from the NEURO-TTRansform study (NCT04136184) showed that treatment with eplontersen (Ionis Pharmaceuticals) resulted in halted neuropathy progression and improved quality of life at 85 weeks in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Currently under review with the FDA, a...
Alternative Titles
Full title
Eplontersen Continues to Show Long-Term Effectiveness in hATTR Polyneuropathy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_reports_2841282255
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_reports_2841282255
Other Identifiers
ISSN
2767-4258
E-ISSN
2767-4266
